Sector
PharmaceuticalsOpen
₹4.32Prev. Close
₹4.27Turnover(Lac.)
₹2.05Day's High
₹4.32Day's Low
₹4.152 Week's High
₹6.8752 Week's Low
₹3.82Book Value
₹1.37Face Value
₹1Mkt Cap (₹ Cr.)
22.57P/E
420EPS
0.01Divi. Yield
01 Aug 2024
12:00 AM
AGM
Announcement Date: 01 Aug, 2024
17 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 5.37 | 5.37 | 5.37 | 5.37 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1.96 | 1.86 | 1.78 | 1.47 |
Net Worth | 7.33 | 7.23 | 7.15 | 6.84 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 13.73 | 11.97 | 9.51 | 4.79 |
yoy growth (%) | 14.69 | 25.93 | 98.53 | 38.27 |
Raw materials | -8.2 | -7.36 | -5.43 | -2.81 |
As % of sales | 59.72 | 61.44 | 57.13 | 58.71 |
Employee costs | -1.32 | -1.21 | -0.97 | -0.9 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 0.55 | 0.58 | 0.39 | -0.17 |
Depreciation | -0.25 | -0.25 | -0.27 | -0.3 |
Tax paid | -0.11 | -0.01 | -0.12 | 0.01 |
Working capital | 0.44 | 0.79 | 0.6 | -0.09 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 14.69 | 25.93 | 98.53 | 38.27 |
Op profit growth | -34.7 | -1.7 | 807.39 | -126 |
EBIT growth | -4.22 | 45.32 | -345.15 | -64.66 |
Net profit growth | -22.22 | 106.71 | -279.86 | -51.01 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,703.25 | 95.58 | 4,08,666.73 | 2,000.46 | 0.94 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,785.4 | 81.57 | 1,80,131.05 | 667 | 0.44 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,482.45 | 24.88 | 1,19,745.08 | 1,485.4 | 1.08 | 4,254.47 | 397.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,504.35 | 62.68 | 1,18,597.8 | 474 | 0.17 | 2,385 | 224.34 |
Mankind Pharma Ltd MANKIND | 2,640.6 | 57.84 | 1,08,985.15 | 382.46 | 0 | 2,126.59 | 354.71 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Mahendra C Raycha
Non Executive Director
Neela Raycha
Non Executive Director
Atul Thakkar.
Joint Managing Director
Akshit Raycha
Company Sec. & Compli. Officer
Mihir Satishkumar Shah
Independent Director
Parag Dave
Independent Director
Rutvik Sanjaykumar Thakkar
Independent Director
Rajesh Sutaria
504 Iscon Elegance S G Road,
Nr Ananddham Jain Derasar,
Gujarat - 380051
Tel: 91-79-66168889/66168890
Website: http://www.zenithhealthcare.com
Email: mahendrazenith@hotmail.com
E-2/3 Saki Vihar Rd,
Ansa Indl Estate, Saki Naka Andheri-E,
Mumbai - 400 072
Tel: 91-22-40430200
Website: www.bigshareonline.com
Email: info@bigshareonline.com
Summary
Zenith Healthcare Limited, incorporated in 1994, is an ISO 9001:2008 & WHO-cGMP certified company, which is strategically located in Changodar, from Ahmedabad International Airport and 20 Km from the ...
Read More
Reports by Zenith Health Care Ltd
What is the Zenith Health Care Ltd share price today?
What is the Market Cap of Zenith Health Care Ltd?
What is the PE and PB ratio of Zenith Health Care Ltd?
What is the 52 Week High and Low of Zenith Health Care Ltd?
What is the CAGR of Zenith Health Care Ltd?
What is the shareholding pattern of Zenith Health Care Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.